Novo Nordisk A/S (NYSE:NVO) Trading Up 0.2% – What’s Next?

Novo Nordisk A/S (NYSE:NVO)’s share price shot up 0.2% during mid-day trading on Tuesday . The stock traded as high as $82.57 and last traded at $80.31. 2,009,699 shares were traded during mid-day trading, a decline of 63% from the average session volume of 5,387,831 shares. The stock had previously closed at $80.15.

Analysts Set New Price Targets

A number of equities research analysts recently commented on NVO shares. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 13th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

The company has a market capitalization of $354.12 billion, a PE ratio of 23.99, a PEG ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The business’s 50-day moving average is $83.67 and its 200-day moving average is $101.82.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is 47.72%.

Institutional Trading of Novo Nordisk A/S

Institutional investors have recently added to or reduced their stakes in the business. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the third quarter valued at $28,000. Center for Financial Planning Inc. raised its position in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL lifted its stake in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares during the period. Park Square Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $29,000. Finally, Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter worth approximately $33,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.